Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data. (May 2015)

• Record Type: Journal Article
• Authors: Bonthapally, Vijayveer; Wu, Eric; Macalalad, Alexander; Yang, Hongbo; Shonukan, Oluwatoyin; Liu, Yi; Chi, Andy; Huebner, Dirk
• Is Part Of: Current medical research and opinion. Volume 31:Number 5(2015:May)
• Page Start: 993
• Page End: 1001
• Publication Date: 2015-05
• Subjects: Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1185/03007995.2015.1030378
• Languages: English
• ISSNs: 0300-7995

Abstract

<abstract> <title>Abstract</title> <sec id="ss1"> <title>Objective:</title> <p>This meta-analysis evaluated the antitumor activity of brentuximab vedotin versus historical values in patients with relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplantation (ASCT).</p> </sec> <sec id="ss2"> <title>Methods:</title> <p>A systematic literature review identified studies (1993–February 2013) reporting complete remission (CR) rates in patients with relapsed/refractory Hodgkin lymphoma post-ASCT. Publications reporting CR rates, identified through interrogation of multiple electronic databases and manual searches (with search terms used to capture 'relapsed', 'refractory', 'HL', and 'ASCT'), were included if they reported: ≥20 relapsed/refractory Hodgkin lymphoma patients, where ≥80% were aged ≥12 years and ≥50% had failed prior ASCT. Overall CR rate was determined using a random-effect model, and compared with that reported for brentuximab vedotin in a pivotal phase 2 trial (SG035-0003).</p> </sec> <sec id="ss3"> <title>Main outcome measures:</title> <p>Across 17 evaluable studies of historical or experimental agents (<italic>n</italic> = 812), the estimated overall CR rate was 11.1% (95% confidence interval [CI] 7.0, 17.6; range, 0–38.5%) versus 33.3% (95% CI 25.3, 43.9) for brentuximab vedotin (<italic>p</italic> < 0.0001). In sensitivity analyses, the estimated overall CR rates for historical/experimental agents were 13.6% (95% CI 8.7, 21.4) when only HL trials that reported a CR rate of >0% were included (13 studies; <italic>n</italic> = 696; <italic>p</italic> = 0.0009 vs. brentuximab vedotin), and 9.0% (95% CI 4.9, 16.6) when only HL trials were included where CR definition was reported and was measured using the same criteria as in the SG035-0003 study (12 studies; <italic>n</italic> = 562; <italic>p</italic> = 0.0001 vs. brentuximab vedotin).</p> </sec> <sec id="ss4"> <title>Conclusions:</title> <p>Indirect comparisons against a heterogeneous historical sample population naturally limit our ability to draw comparisons, yet the results from this quantitative meta-analysis suggest that the antitumor activity of brentuximab vedotin may exceed that of other therapies used to treat patients with relapsed/refractory Hodgkin lymphoma post-ASCT.</p> </sec> </abstract>